Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoLithium NP03
- Development stage
- Phase 2
- Lead developer
- Medesis Pharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Buccal (oro-mucosal)
01
Overview
NanoLithium NP03 is a **microdose lithium citrate formulation** developed for the treatment of Alzheimer's disease. It utilizes the specialized **AONYS reverse microemulsion delivery system** designed to administer nano micelles via the buccal (oro-mucosal) route. The drug's mechanism of action includes: inhibition of **glycogen synthase kinase 3 beta (GSK-3β)**, reduction of **beta-site APP cleaving enzyme 1 (BACE1) expression and activity**, induction of **neurogenesis and synaptic plasticity**, lowering soluble and insoluble **amyloid-beta (Aβ) peptide levels**, reduction of **neuroinflammation** markers (e.g., IL-6, CXCL1, 4-hydroxynonenal), and protection of **cholinergic bouton density**. In clinical and preclinical studies, NP03 has demonstrated the ability to correct cognitive deficits, reduce amyloid pathology, and modulate neuropsychiatric symptoms in Alzheimer's disease[1][3][4][5][6].
- Brand names
- NanoLithium NP03
- Other names
- NP03NP-03NP 03NanoLithium
02
Targets
BACE1 (Beta-site APP-cleaving enzyme 1)GSK3 (Glycogen synthase kinase 3 beta)Aβ (Amyloid-beta peptides and aggregates)SLC18A3 (Vesicular acetylcholine transporter)
Beyond the preview
Go deeper on NanoLithium NP03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoLithium NP03.